Key points are not available for this paper at this time.
These results support the use of PI3K inhibitors to control T cell responses and show the potential utility of the dual PI3K/mTOR inhibitor BEZ235 in GvHD prophylaxis.
Herrero‐Sánchez et al. (Thu,) studied this question.